Jefferies, GSK
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50 ... and few near-term catalysts to “rebuild belief” suggests the stock’s value disconnect ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance ...
GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.
This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...
Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% ...
GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...
GSK plc GSK reported third-quarter 2024 core ... The upside was partially offset by the removal of the Average Manufacturer Price cap on Medicaid drug prices in the United States, adversely ...
Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...
GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales ...
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
The firm has removed its price target for GSK, previously set to guide investors on the stock's potential value. The downgrade reflects concerns about the limited upside in the company's ...
Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback